ILLUMINA, INC. (ILMN) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The "Razor-Blade" Toll Bridge: Illumina doesn't just sell machines; they sell the permission to do genomic science. Once a lab installs a sequencer and validates their protocols on Illumina chemistry, the cost of switching isn't just financial—it's a regulatory and operational nightmare.
• Exceptional Unit Economics: The hardware is the hook; the consumables are the harvest. High-margin, recurring revenue that grows as the cost of sequencing drops and the volume of tests explodes. This is a compounding machine hidden inside a biotech wrapper.
• The Genomic Secular Trend: Personalized medicine is not a fad; it is the future of healthcare. As sequencing moves from "research" to "routine clinical diagnosis," the total addressable market expands exponentially.
• Attractive Entry: Berkshire doesn't buy "stories," we buy cash flows at a discount. If the market continues to punish them for the GRAIL debacle—which is now behind them—we are buying a dominant monopoly at a distressed price.
• Target Range: Genuinely attractive below $130, where the market has fully priced in the management incompetence and we are paying for the moat.

🐻 The Bear Case (Charlie inverts)

“Show me where I'll die and I won't go there.”

• The "Next Big Thing" Leapfrog: The biggest risk isn't a recession; it's a paradigm shift. If a competitor (e.g., Ultima Genomics or a new nanopore tech) delivers a 10x reduction in cost or a 10x increase in speed, Illumina’s installed base becomes a graveyard of expensive, obsolete hardware.
• The Commoditization Trap: DNA sequencing is trending toward a utility. If the "proprietary chemistry" is cracked or becomes a commodity, the margins on consumables collapse. We move from a "toll bridge" to a "price war."
• Management Hubris: The GRAIL acquisition was more than a mistake; it was organizational blindness. If the culture still rewards "visionary" ego over capital discipline, they will find another way to incinerate billions of dollars.
• The Verdict on Risk: Technological leapfrogging is the most likely killer. Timeframe: 3–7 years. If the "razor" becomes obsolete, the "blades" are worthless.

💰 Valuation & Margin of Safety

Reacting to the DCF estimate of $171.08:

• Intrinsic value estimate: $171.08 per share
• 25% margin of safety entry: $128.31 (conservative)
• 50% margin of safety entry: $85.54 (Buffett's ideal)

Current Status: Fairly valued to slightly cheap relative to the DCF, but dangerously expensive relative to the risk of technological disruption. The DCF assumes a steady 11.7% growth, but fails to account for the binary risk of a superior technology emerging.

Verdict: WATCH

The moat is wide, but the bridge is shaking from management's previous failures. We do not buy based on a DCF that ignores the risk of obsolescence. We wait for a price closer to $120 to ensure the margin of safety outweighs the innovation risk.